Seeing Is Believing
Currently out of the existing stock ratings of Jason Gerberry, 152 are a BUY (64.96%), 55 are a HOLD (23.5%), 27 are a SELL (11.54%).
Analyst Jason Gerberry, currently employed at BAML, carries an average stock price target met ratio of 59.74% that have a potential upside of 24.08% achieved within 249 days.
Jason Gerberry’s has documented 495 price targets and ratings displayed on 51 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on AXSM, Axsome Therapeutics at 11-Feb-2025.
Analyst best performing recommendations are on CORI (CORIUM INTERNATIONAL).
The best stock recommendation documented was for KRTX (KARUNA THERAPEUTICS) at 8/9/2022. The price target of $261 was fulfilled within 2 days with a profit of $32.55 (14.25%) receiving and performance score of 71.24.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$214
$21.13 (10.96%)
$221
18 days ago
(03-Feb-2025)
22/24 (91.67%)
$23.86 (12.55%)
449
Buy
$217
$24.13 (12.51%)
$211
18 days ago
(03-Feb-2025)
0/3 (0%)
$26.86 (14.13%)
Buy
$220
$27.13 (14.07%)
$195
18 days ago
(03-Feb-2025)
11/12 (91.67%)
$29.86 (15.70%)
342
Hold
$190
$-2.87 (-1.49%)
$200
18 days ago
(03-Feb-2025)
15/15 (100%)
$-0.14 (-0.07%)
259
Buy
$215
$22.13 (11.47%)
$205
18 days ago
(03-Feb-2025)
9/13 (69.23%)
$24.86 (13.07%)
359
Which stock is Jason Gerberry is most bullish on?
Which stock is Jason Gerberry is most reserved on?
What Year was the first public recommendation made by Jason Gerberry?